Ziihera regimens cleared for first-line HER2+ gastroesophageal adenocarcinoma

What this means

Ziihera is a targeted antibody drug that attaches to the HER2 protein on certain cancer cells. The FDA has approved its use, combined with the immunotherapy tislelizumab and chemotherapy, as an initial treatment for advanced HER2-positive stomach and esophageal cancers. This approval provides a new, first-line combination therapy option for patients with these aggressive cancers.